Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:ELEV NASDAQ:FATE NASDAQ:IPSC NYSE:JNJ NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.63+4.2%$2.70$0.91▼$4.12$235.14M2.162.82 million shs1.38 million shsELEVElevation Oncology$0.37$0.37$0.22▼$3.09$21.62M1.481.18 million shsN/AFATEFate Therapeutics$0.97-0.3%$1.11$0.66▼$4.20$111.29M2.212.00 million shs1.13 million shsIPSCCentury Therapeutics$0.50+4.8%$0.55$0.34▼$1.86$43.37M1.78723,047 shs438,141 shsJNJJohnson & Johnson$176.67-1.2%$168.06$140.68▼$181.16$427.14B0.48.93 million shs3.50 million shsYMABY-mAbs Therapeutics$8.58+0.1%$6.34$3.55▼$16.11$389.65M0.54536,110 shs181,566 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+0.80%-4.91%-3.08%+31.94%-28.00%ELEVElevation Oncology0.00%0.00%0.00%+14.10%-45.47%FATEFate Therapeutics-3.00%-10.19%-10.19%-39.38%-72.44%IPSCCentury Therapeutics+2.26%-4.26%-14.19%-22.31%-69.89%JNJJohnson & Johnson+0.53%+1.79%+4.66%+15.24%+6.80%YMABY-mAbs Therapeutics-0.12%+0.35%+0.59%+62.62%-40.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.63+4.2%$2.70$0.91▼$4.12$235.14M2.162.82 million shs1.38 million shsELEVElevation Oncology$0.37$0.37$0.22▼$3.09$21.62M1.481.18 million shsN/AFATEFate Therapeutics$0.97-0.3%$1.11$0.66▼$4.20$111.29M2.212.00 million shs1.13 million shsIPSCCentury Therapeutics$0.50+4.8%$0.55$0.34▼$1.86$43.37M1.78723,047 shs438,141 shsJNJJohnson & Johnson$176.67-1.2%$168.06$140.68▼$181.16$427.14B0.48.93 million shs3.50 million shsYMABY-mAbs Therapeutics$8.58+0.1%$6.34$3.55▼$16.11$389.65M0.54536,110 shs181,566 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+0.80%-4.91%-3.08%+31.94%-28.00%ELEVElevation Oncology0.00%0.00%0.00%+14.10%-45.47%FATEFate Therapeutics-3.00%-10.19%-10.19%-39.38%-72.44%IPSCCentury Therapeutics+2.26%-4.26%-14.19%-22.31%-69.89%JNJJohnson & Johnson+0.53%+1.79%+4.66%+15.24%+6.80%YMABY-mAbs Therapeutics-0.12%+0.35%+0.59%+62.62%-40.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.23Hold$5.1093.55% UpsideELEVElevation Oncology 2.00Hold$2.62616.89% UpsideFATEFate Therapeutics 2.14Hold$3.30238.11% UpsideIPSCCentury Therapeutics 3.00Buy$3.75657.58% UpsideJNJJohnson & Johnson 2.65Moderate Buy$176.29-1.65% DownsideYMABY-mAbs Therapeutics 1.80Reduce$9.6212.21% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025EDITEditas MedicineWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$3.00 ➝ $4.008/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$185.00 ➝ $200.008/15/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $5.008/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $6.008/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.508/6/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$11.00 ➝ $8.608/5/2025YMABY-mAbs TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$8.608/5/2025YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$26.00 ➝ $8.608/5/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform8/5/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$8.60(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M7.33N/AN/A$1.63 per share1.62ELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/AFATEFate Therapeutics$13.63M8.26N/AN/A$2.80 per share0.35IPSCCentury Therapeutics$6.59M6.49N/AN/A$1.90 per share0.26JNJJohnson & Johnson$88.82B4.86$13.21 per share13.57$29.69 per share6.04YMABY-mAbs Therapeutics$87.68M4.44N/AN/A$2.05 per share4.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)ELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%11/4/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)IPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-11.53%-6.94%11/4/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3519.1516.192.2725.00%32.49%13.00%10/21/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%11/14/2025 (Estimated)Latest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IPSCCentury Therapeutics-$0.38-$0.38N/A-$0.38$0.03 millionN/A8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/8/2025Q2 2025YMABY-mAbs Therapeutics-$0.27-$0.07+$0.20-$0.07$18.40 million$19.52 million7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.90%N/A55.61%64 YearsYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ALatest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A2.772.77ELEVElevation Oncology0.6719.4019.40FATEFate TherapeuticsN/A8.048.04IPSCCentury TherapeuticsN/A10.7210.72JNJJohnson & Johnson0.501.010.76YMABY-mAbs TherapeuticsN/A4.003.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%ELEVElevation Oncology83.70%FATEFate Therapeutics97.54%IPSCCentury Therapeutics50.20%JNJJohnson & Johnson69.55%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine2.10%ELEVElevation Oncology8.10%FATEFate Therapeutics5.51%IPSCCentury Therapeutics5.00%JNJJohnson & Johnson0.16%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23089.92 million88.03 millionOptionableELEVElevation Oncology4059.22 million54.43 millionOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableIPSCCentury Therapeutics17086.39 million82.07 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableYMABY-mAbs Therapeutics15045.44 million36.49 millionOptionableYMAB, IPSC, EDIT, FATE, JNJ, and ELEV HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. $YMAB Shares Bought by Wellington Management Group LLPSeptember 2 at 3:58 AM | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?September 1, 2025 | zacks.comY-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLCSeptember 1, 2025 | marketbeat.comStonepine Capital Management LLC Acquires New Stake in Y-mAbs Therapeutics, Inc. $YMABAugust 26, 2025 | marketbeat.comBrokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $9.62August 26, 2025 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Reduce" from AnalystsAugust 25, 2025 | marketbeat.comY-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comY-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comXTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)August 10, 2025 | marketbeat.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comY-mAbs (YMAB) Q2 Revenue Falls 14%August 9, 2025 | aol.comAFederated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)August 9, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2025 | zacks.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to HoldAugust 8, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor FitzgeraldAugust 8, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist FinancialAugust 8, 2025 | marketbeat.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7, 2025 | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025Worried About a Fading Rally? Consider These 3 Dividend StocksBy Dan Schmidt | August 11, 2025YMAB, IPSC, EDIT, FATE, JNJ, and ELEV Company DescriptionsEditas Medicine NASDAQ:EDIT$2.62 +0.11 (+4.17%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Elevation Oncology NASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Fate Therapeutics NASDAQ:FATE$0.97 0.00 (-0.30%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Century Therapeutics NASDAQ:IPSC$0.50 +0.02 (+4.85%) As of 02:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Johnson & Johnson NYSE:JNJ$176.67 -2.09 (-1.17%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Y-mAbs Therapeutics NASDAQ:YMAB$8.57 +0.01 (+0.06%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
